Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
Peptides vaccination is an interesting approach to activate T-cells toward desired antigens in hematological malignancies. In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR m...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02264/full |
| _version_ | 1819129711058485248 |
|---|---|
| author | Uffe Klausen Staffan Holmberg Staffan Holmberg Morten Orebo Holmström Morten Orebo Holmström Nicolai Grønne Dahlager Jørgensen Jacob Handlos Grauslund Jacob Handlos Grauslund Inge Marie Svane Inge Marie Svane Mads Hald Andersen Mads Hald Andersen |
| author_facet | Uffe Klausen Staffan Holmberg Staffan Holmberg Morten Orebo Holmström Morten Orebo Holmström Nicolai Grønne Dahlager Jørgensen Jacob Handlos Grauslund Jacob Handlos Grauslund Inge Marie Svane Inge Marie Svane Mads Hald Andersen Mads Hald Andersen |
| author_sort | Uffe Klausen |
| collection | DOAJ |
| description | Peptides vaccination is an interesting approach to activate T-cells toward desired antigens in hematological malignancies. In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR mutations, and antigens from immune regulatory proteins in the tumor microenvironment such as programmed death 1 ligands (PD-L1 and PD-L2). Immunosuppressive defenses of tumors are an important challenge to overcome and the T cell suppressive ligands PD-L1 and PD-L2 are often present in tumor microenvironments. Thus, PD-L1 and PD-L2 are interesting targets for peptide vaccines in diseases where the tumor microenvironment is known to play an essential role such as multiple myeloma and follicular lymphoma. In myelodysplastic syndromes the drug azacitidine re-exposes tumor associated antigens, why vaccination with related peptides would be an interesting addition. In myeloproliferative neoplasms the JAK2 and CALR mutations has proven to be immunogenic neo-antigens and thus possible targets for peptide vaccination. In this mini review we summarize the basis for these novel approaches, which has led to the initiation of clinical trials with various peptide vaccines in myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and follicular lymphoma. |
| first_indexed | 2024-12-22T08:48:03Z |
| format | Article |
| id | doaj.art-3d513f2aa19544f291c1f4374c46bb98 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T08:48:03Z |
| publishDate | 2018-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3d513f2aa19544f291c1f4374c46bb982022-12-21T18:32:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-10-01910.3389/fimmu.2018.02264410962Novel Strategies for Peptide-Based Vaccines in Hematological MalignanciesUffe Klausen0Staffan Holmberg1Staffan Holmberg2Morten Orebo Holmström3Morten Orebo Holmström4Nicolai Grønne Dahlager Jørgensen5Jacob Handlos Grauslund6Jacob Handlos Grauslund7Inge Marie Svane8Inge Marie Svane9Mads Hald Andersen10Mads Hald Andersen11Center for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, DenmarkDepartment of Hematology, Herlev Hospital, Herlev, DenmarkDivision of Immunology - T cells & Cancer, DTU Nanotech, Technical University of Denmark, Lyngby, DenmarkCenter for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, DenmarkDepartment of Hematology, Zealand University Hospital, Roskilde, DenmarkCenter for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, DenmarkCenter for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, DenmarkDepartment of Hematology, Zealand University Hospital, Roskilde, DenmarkCenter for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, DenmarkInstitute for Clinical Medicine, University of Copenhagen, Copenhagen, DenmarkCenter for Cancer Immune Therapy, Herlev Hospital, Department of Hematology and Oncology, Herlev, DenmarkInstitute for Immunology and Microbiology, University of Copenhagen, Copenhagen, DenmarkPeptides vaccination is an interesting approach to activate T-cells toward desired antigens in hematological malignancies. In addition to classical tumor associated antigens, such as cancer testis antigens, new potential targets for peptide vaccination comprise neo-antigens including JAK2 and CALR mutations, and antigens from immune regulatory proteins in the tumor microenvironment such as programmed death 1 ligands (PD-L1 and PD-L2). Immunosuppressive defenses of tumors are an important challenge to overcome and the T cell suppressive ligands PD-L1 and PD-L2 are often present in tumor microenvironments. Thus, PD-L1 and PD-L2 are interesting targets for peptide vaccines in diseases where the tumor microenvironment is known to play an essential role such as multiple myeloma and follicular lymphoma. In myelodysplastic syndromes the drug azacitidine re-exposes tumor associated antigens, why vaccination with related peptides would be an interesting addition. In myeloproliferative neoplasms the JAK2 and CALR mutations has proven to be immunogenic neo-antigens and thus possible targets for peptide vaccination. In this mini review we summarize the basis for these novel approaches, which has led to the initiation of clinical trials with various peptide vaccines in myelodysplastic syndromes, myeloproliferative neoplasms, multiple myeloma, and follicular lymphoma.https://www.frontiersin.org/article/10.3389/fimmu.2018.02264/fullpeptide vaccinationfollicular lymphomamultiple myelomamyeloproliferative neoplasmsmyelodysplastic syndromePD-1 |
| spellingShingle | Uffe Klausen Staffan Holmberg Staffan Holmberg Morten Orebo Holmström Morten Orebo Holmström Nicolai Grønne Dahlager Jørgensen Jacob Handlos Grauslund Jacob Handlos Grauslund Inge Marie Svane Inge Marie Svane Mads Hald Andersen Mads Hald Andersen Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies Frontiers in Immunology peptide vaccination follicular lymphoma multiple myeloma myeloproliferative neoplasms myelodysplastic syndrome PD-1 |
| title | Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies |
| title_full | Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies |
| title_fullStr | Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies |
| title_full_unstemmed | Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies |
| title_short | Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies |
| title_sort | novel strategies for peptide based vaccines in hematological malignancies |
| topic | peptide vaccination follicular lymphoma multiple myeloma myeloproliferative neoplasms myelodysplastic syndrome PD-1 |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2018.02264/full |
| work_keys_str_mv | AT uffeklausen novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT staffanholmberg novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT staffanholmberg novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT mortenoreboholmstrom novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT mortenoreboholmstrom novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT nicolaigrønnedahlagerjørgensen novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT jacobhandlosgrauslund novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT jacobhandlosgrauslund novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT ingemariesvane novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT ingemariesvane novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT madshaldandersen novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies AT madshaldandersen novelstrategiesforpeptidebasedvaccinesinhematologicalmalignancies |